Acute Myeloid Leukemia Clinical Trial
Official title:
Gentuzumab Ozogamicin Berfore Allogeneic Stem Cell Transplantation in Patients With Relapsed CD33+ Acute Myeloid Leukemia
Study Design:
prospective phase II trial with 30 patients in 1 site
Treatment Scheme:
Option 1: Patient < 60 years of age with relapse after chemotherapy or > 12 months after
hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14
Fludarabin 30 mg/ m² day –6 to –3 TBI 2x2 Gy day –3 to –2 (total dose 8 Gy) Tacrolimus (level
adapted) from day –3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to day 40 PBSC day 0
Option 2: Patient > 60 years of age or younger patients < 12 Months after hematopoetic stem
cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14 Fludarabin 30 mg/ m²
day –3 to –1 TBI 1x2 Gy day 0 (total dose 2 Gy) Tacrolimus (level adapted) from day –3 on
Mycophenolat 2 x 1000 mg p.o. from day 0 to 40 PBSC day 0
Scientific/Medical Rationale (Objective):
Primary:
documentation of the extramedullary toxicity of the standard therapy
Secondary:
Induction of a persistent remission by the combination of Mylotarg and dose reduced
conditioning followed by allogenic hematopoetic stem cell transplantation in patients with
relapsed acute myelotic leukemia
Study Design:
prospective phase II trial with 30 patients in 1 site
Treatment Scheme:
Option 1: Patient < 60 years of age with relapse after chemotherapy or > 12 months after
hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14
Fludarabin 30 mg/ m² day –6 to –3 TBI 2x2 Gy day –3 to –2 (total dose 8 Gy) Tacrolimus (level
adapted) from day –3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to day 40 PBSC day 0
Option 2: Patient > 60 years of age or younger patients < 12 Months after hematopoetic stem
cell transplantation Mylotarg 6 mg/ m² day –21 Mylotarg 3 mg/ m² day –14 Fludarabin 30 mg/ m²
day –3 to –1 TBI 1x2 Gy day 0 (total dose 2 Gy) Tacrolimus (level adapted) from day –3 on
Mycophenolat 2 x 1000 mg p.o. from day 0 to 40 PBSC day 0
Patient Population to be Included:
30 patients
Primary and Secondary Efficacy Endpoints:
See point: Scientific/Medical Rationale
Inclusion Criteria /Exclusion Criteria:
- patients with acute myelotic leukemia and expression of CD33 on > 5% of blasts in bone
marrow
- relapse after chemotherapy
- relapse after autologous or allogenic hematopoetic stem cell transplantation
- pts. in 2nd remission after chemotherapy and ineligible for a conventional allogeneic
transplantation
- age: 18-70 years
- informed consent of the patient
- ASAT/ ALAT < 3fold of upper standard
- Bilirubin < 2fold of upper standard
- ejection fraction > 40% in echocardiography
- potential donor in accordance with the following priorities:
- 1st HLA-identical related donor (HLA *A, *B, *C and *DR)
- 2nd HLA-identical non-related donor with the maximum of 1 allelmismatch (DNA typing A,
B, C, DRB1, DQB1)
Study Procedures:
See point . Study Design
Safety Endpoints/ Statistical Considerations:
Thirty patients will be treated, which will yield a 95% confidence interval for non-relapse
mortality with a precision of +/- 14%. Data will be evaluated after groups of 10 and 20
patients. If results at those times suggest with greater than 80% confidence that the true
rate of day 100 non-relapse mortality exceeds 20%, then the trial will be stopped.
Operationally, this will occur if 4 out of 10 or 7 out of 20 patients have non-relapse
deaths. Should the requisite number of deaths be reached before the 10 or 20 patient
benchmarks, then the trial will be stopped at that time.
A dose reduction of mylotarg from 9 to 6 mg/m2 will be performed if the likelihood of grade 4
liver-toxicity as defined by bilirubine, AST and symptoms of sinusoidal obstruction syndrome
is > 20%. This will be the case if 4 out of the first ten patients experience grade 4 liver
toxicity. The second dose of mylotarg will then be omitted in the next ten patients. If the
rate of liver-toxicity in the next 10 patients remains unchanged, the study will be stopped.
The stopping rules will be discussed and enforced by the protocol committee and transmitted
to each local IRB asap.
The following safety endpoints will be documented:
1. Incidence of neurological toxicity
2. Incidence of liver toxicity
3. Incidence of acute gastrointestinal toxicity
4. Incidence and severity of mucositis
5. Incidence of pulmonary toxicity
6. Incidence of systemic infections
7. Duration of neutropenia Severe adverse events (SAE) will have to be reported to the
principal investigator within 24 hours after occurrence. It will be his responsibility
to inform the IRB and the sponsor or the trial, if adequate.
SAE compromise: death before relapse of leukemia, illness with life-threatening character,
severe illness requiring hospitalization, illness leading to prolonged disabilities, second
cancer developing after treatment.
SAE will have to be reported on special forms contained in the CRF
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |